Par Acquisition By TPG Allows Competing Marriage Proposals
This article was originally published in The Pink Sheet Daily
Executive Summary
Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.
You may also be interested in...
Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par
J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.
Endo Continues To Expand Generics Business With Par Acquisition
After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.
Par Enters Generic Injectable Market Via JHP Buy
The generics maker is expanding its portfolio of reformulations through the acquisition of privately-held JHP in a deal worth $490 million, expected to close in short order.